Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study

被引:1
|
作者
He, Yong-Gang [1 ]
Huang, Xiao-Bing [1 ]
Li, Yu-Ming [1 ]
Li, Jing [1 ]
Peng, Xue-Hui [1 ]
Huang, Wen [1 ]
Tang, Yi-Chen [1 ]
Zheng, Lu [1 ,2 ]
机构
[1] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, Chongqing 400037, Peoples R China
[2] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, 183 Xinqiao High St, Chongqing 400037, Peoples R China
关键词
Pancreatic ductal adenocarcinoma; Neoadjuvant chemotherapy; Laparoscopic pancreaticoduodenectomy; Laparoscopic radical antegrade modular pancreatosplenectomy; Complications; INTERNATIONAL STUDY-GROUP; UPFRONT RESECTION; CANCER; PANCREATICODUODENECTOMY; DEFINITION; SURGERY; TUMORS;
D O I
10.4251/wjgo.v14.i9.1785
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Multiple studies have demonstrated that neoadjuvant chemotherapy (NACT) can prolong the overall survival of pancreatic ductal adenocarcinoma (PDAC) patients. However, most studies have focused on open surgery following NACT. AIM To investigate the efficacy and safety of laparoscopic radical resection following NACT for PDAC. METHODS We retrospectively analyzed the clinical data of 15 patients with pathologically confirmed PDAC who received NACT followed by laparoscopic radical surgery in our hospital from December 2019 to April 2022. All patients underwent abdominal contrast-enhanced computed tomography (CT) and positron emission tomography-CT before surgery to accurately assess tumor stage and exclude distant metastasis. RESULTS All 15 patients with pancreatic cancer were successfully converted to surgical resection after NACT, including 8 patients with pancreatic head cancer and 7 patients with pancreatic body and tail cancer. Among them, 13 patients received the nab-paclitaxel plus gemcitabine regimen (gemcitabine 1000 mg/m(2) plus nab-paclitaxel 125 mg/m(2) on days 1, 8, and 15 every 4 wk) and 2 patients received the modified FOLFIRINOX regimen (intravenous oxaliplatin 68 mg/m(2), irinotecan 135 mg/m(2), and leucovorin 400 mg/m(2) on day 1 and fluorouracil 400 mg/m(2) on day 1, followed by 46-h continuous infusion of fluorouracil 2400 mg/m(2)). After each treatment cycle, abdominal CT, tumor markers, and circulating tumor cell counts were reviewed to evaluate the treatment efficacy. All 15 patients achieved partial remission. The surgical procedures included laparoscopic pancreaticoduodenectomy (LPD, n = 8) and laparoscopic radical antegrade modular pancreatosplenectomy (L-RAMPS, n = 7). None of them were converted to a laparotomy. One patient with pancreatic head carcinoma was found to have portal vein involvement during the operation, and LPD combined with vascular resection and reconstruction was performed. The amount of blood loss and operation times of L-RAMPS vs LPD were 435.71 +/- 32.37 mL vs 343.75 +/- 145.01 mL and 272.52 +/- 49.14 min vs 444.38 +/- 68.63 min, respectively. The number of dissected lymph nodes was 16.87 +/- 4.10, and 3 patients had positive lymph nodes. One patient developed grade B postoperative pancreatic fistula (POPF) after L-RAMPS, and one patient experienced jaundice after LPD. None of the patients died after surgery. As of April 2022, progressive disease was noted in 4 patients, 2 patients had liver metastasis, and one had both liver metastasis and lymph node metastasis and died during the follow-up period. CONCLUSION Laparoscopic radical resection of PDAC after NACT is safe and effective if it is performed by a surgeon with rich experience in LPD and in a large center of pancreatic surgery.
引用
收藏
页码:1785 / 1797
页数:13
相关论文
共 50 条
  • [1] Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma:A retrospective study
    Yong-Gang He
    Xiao-Bing Huang
    Yu-Ming Li
    Jing Li
    Xue-Hui Peng
    Wen Huang
    Yi-Chen Tang
    Lu Zheng
    World Journal of Gastrointestinal Oncology, 2022, (09) : 1785 - 1797
  • [2] Safety and Efficacy of Adjuvant Chemoradiation Therapy With Capecitabine After Resection of Pancreatic Ductal Adenocarcinoma A Retrospective Review
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Se Hoon
    Lee, Jong Kyun
    Lee, Kyu Taek
    Lee, Kwang Hyuck
    Heo, Jin-Seok
    Choi, Seong Ho
    Choi, Dong Wook
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Jang, Kee-Taek
    Park, Hee Chul
    Lim, Do Hoon
    Park, Joon Oh
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (05): : 432 - 438
  • [3] Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma
    Yeung, Kai Tai Derek
    Doyle, Joseph
    Kumar, Sacheen
    Aitken, Katharine
    Tait, Diana
    Cunningham, David
    Jiao, Long R.
    Bhogal, Ricky Harminder
    CANCERS, 2024, 16 (02)
  • [4] THE IMPACT OF NEOADJUVANT THERAPY ON VASCULAR RESECTION IN PANCREATIC DUCTAL ADENOCARCINOMA
    Crocker, Andrew B.
    Barrak, Dany
    Hopkins, Steven E.
    Egleston, Brian
    Reddy, Sanjay S.
    GASTROENTEROLOGY, 2023, 164 (06) : S1556 - S1556
  • [5] Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy
    Sohei Satoi
    Hiroaki Yanagimoto
    Tomohisa Yamamoto
    Chisato Ohe
    Chika Miyasaka
    Yoshiko Uemura
    Satoshi Hirooka
    So Yamaki
    Hironori Ryota
    Taku Michiura
    Kentaro Inoue
    Yoichi Matsui
    Noboru Tanigawa
    Masanori Kon
    Surgery Today, 2017, 47 : 84 - 91
  • [6] Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy
    Satoi, Sohei
    Yanagimoto, Hiroaki
    Yamamoto, Tomohisa
    Ohe, Chisato
    Miyasaka, Chika
    Uemura, Yoshiko
    Hirooka, Satoshi
    Yamaki, So
    Ryota, Hironori
    Michiura, Taku
    Inoue, Kentaro
    Matsui, Yoichi
    Tanigawa, Noboru
    Kon, Masanori
    SURGERY TODAY, 2017, 47 (01) : 84 - 91
  • [7] Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study
    Coppola, Alessandro
    Iannone, Immacolata
    Sapienza, Paolo
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (11) : 3692 - 3693
  • [8] Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study
    Zou, Yiping
    Gao, Song
    Yu, Xin
    Zhou, Tianxing
    Xie, Yongjie
    Guo, Xiaofan
    An, Ran
    Wang, Xiuchao
    Zhao, Tiansuo
    Chang, Antao
    Gao, Chuntao
    Yu, Jun
    Hao, Jihui
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (06) : 1573 - 1583
  • [9] Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma
    Brown, Zachary J.
    Shannon, Alexander H.
    Cloyd, Jordan M.
    MINERVA SURGERY, 2024, : 315 - 325
  • [10] Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
    Secanella, Luis
    Busquets, Juli
    Pelaez, Nuria
    Sorribas, Maria
    Laquente, Berta
    Ruiz, Sandra
    Carnaval, Thiago
    Videla, Sebastian
    Fabregat, Juan
    MEDICINE, 2022, 101 (48) : E32126